To market, to market-2012

摘要

This year's To-Market, To-Market chapter provides summaries for 30 compounds that received first-time approval worldwide in 2012. Anticancer treatments dominated the new entries with 14 approvals, including 12 small molecules and 2 monoclonal antibodies. Three new diabetes treatments were introduced, along with three agents for gastrointestinal disorders. The remaining therapeutic areas had 1-2 approvals each. The summaries include indication, information about the disease treated, mechanism of action, selected preclinical data, key steps in the synthesis, pharmacokinetic and metabolism profile, clinical efficacy and safety data, and other key information about the approval.